Neovacs

Report Publication Announcement • Feb 16, 2018

PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

2018 Financial Calendar

Paris, February 16, 2018, 6pm CET – NEOVACS (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2018.

Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.

-	st convocation Shareholders AGM- 1	February 28, 2018
-	nd convocation Shareholders AGM - 2	March 12, 2018
-	2017 Full-Year Results	March 30, 2018
-	st convocation Shareholders' Annual General Assembly- 1	May 15, 2018
-	nd Shareholders' Annual General Assembly- 2 convocation	May 28, 2018
-	2018 Half-Year Results	October 30, 2018

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 00 cmasson@neovacs.com

LIFE SCIENCE ADVISORS- Investor Relations / Financial Communications Chris Maggos chris@lifesciadvisors.com